Prostate Cancer

Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses next steps following the 10-year PROTECT study data for patients with prostate cancer.

Stephen J. Freedland, MD, shares his insight on how to counsel patients with prostate cancer on the benefits of leading a healthier life.

Timothy J. Daskivich, MD, discusses the use of High-intensity focused ultrasound and other treatment strategies in the prostate cancer armamentarium.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the promise of GnRH antagonists in prostate cancer.

The NCCN now lists apalutamide (Erleada) as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the role of precision medicine in prostate cancer.

Edwin M. Posadas, MD, discusses the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.

Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses traditional imaging modalities and newer counterparts that are used to detect prostate cancer.